[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

# ![@OncLive Avatar](https://lunarcrush.com/gi/w:26/cr:twitter::43051682.png) @OncLive OncLive.com

OncLive.com posts on X about matterhorn, momentum, $abbv, $fro the most. They currently have XXXXXX followers and 1451 posts still getting attention that total XXX engagements in the last XX hours.

### Engagements: XXX [#](/creator/twitter::43051682/interactions)
![Engagements Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::43051682/c:line/m:interactions.svg)

- X Week XXXXX -XX%
- X Month XXXXXX +22%
- X Months XXXXXXX +3.20%
- X Year XXXXXXX -XX%

### Mentions: X [#](/creator/twitter::43051682/posts_active)
![Mentions Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::43051682/c:line/m:posts_active.svg)

- X Week XX -XX%
- X Month XX -XXXX%
- X Months XXX +7.50%
- X Year XXX -XX%

### Followers: XXXXXX [#](/creator/twitter::43051682/followers)
![Followers Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::43051682/c:line/m:followers.svg)

- X Week XXXXXX +0.19%
- X Month XXXXXX +0.65%
- X Months XXXXXX +3.30%
- X Year XXXXXX +6%

### CreatorRank: XXXXXXXXX [#](/creator/twitter::43051682/influencer_rank)
![CreatorRank Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::43051682/c:line/m:influencer_rank.svg)

### Social Influence [#](/creator/twitter::43051682/influence)
---

**Social category influence**
[travel destinations](/list/travel-destinations)  [stocks](/list/stocks)  [currencies](/list/currencies) 

**Social topic influence**
[matterhorn](/topic/matterhorn), [momentum](/topic/momentum), [$abbv](/topic/$abbv), [$fro](/topic/$fro)

**Top assets mentioned**
[AbbVie Inc (ABBV)](/topic/$abbv) [Frontline Ltd. (FRO)](/topic/$fro)
### Top Social Posts [#](/creator/twitter::43051682/posts)
---
Top posts by engagements in the last XX hours

"Important data from the #MATTERHORN study shared by Dr @TaberneroJosep at #ESMO25 confirming an OS benefit in the FLOT + Durvalumab arm in the ITT population (HR XXXX XX% CI 0.63-0.96 p=0.021). Benefit enriched in PD-L1 TAP X% but also seen in X% group. Key finding that higher nodal clearance and pathologic response translates to EFS and OS in D+FLOT group. Major progress made since the MAGIC trial nearly XX years ago. @Jonathanwlee23 #CancerResearch #Oncology #MedTwitter"  
[X Link](https://x.com/OncLive/status/1979168743545581913) [@OncLive](/creator/x/OncLive) 2025-10-17T12:52Z 48.5K followers, XXX engagements


"Kicking off #ESMO25 with exciting updates on the role of DLL-3 in NEC. Its encouraging to see growing momentum in drug development for this rare but aggressive cancer. DLL-3 expression is emerging as a promising biomarker in extra-pulmonary NECs. Notably DLL-3 high (50%) expression was seen in about half of the cohortso definitely not a needle in a haystack. For those following this space dont miss the Dareon-5 abstract at ESMO"  
[X Link](https://x.com/OncLive/status/1980162386670535129) [@OncLive](/creator/x/OncLive) 2025-10-20T06:41Z 48.5K followers, 3123 engagements


"AbbVie Files BLA for First Hematologic ADC Pivekimab Sunirine In CADENZA pivekimab achieved a XX% cCR and XX% ORR in frontline BPDCN. Details here:"  
[X Link](https://x.com/OncLive/status/1980061399129673812) [@OncLive](/creator/x/OncLive) 2025-10-19T23:59Z 48.5K followers, XXX engagements


"ctDNA Clearance With Adjuvant Therapy Is Associated With Improved DFS in CRC @EmerikOsterlund @MDAndersonNews @myESMO #ESMO25"  
[X Link](https://x.com/OncLive/status/1982025589000159568) [@OncLive](/creator/x/OncLive) 2025-10-25T10:04Z 48.5K followers, XXX engagements